Abridge Newsjust landed in the App Store.
The Quick Facts
- Yesterday, the Court of Arbitration for Sport (CAS) issued a ruling in a controversial case regarding Caster Semenya, an elite female track and field athlete and 2016 Olympic gold medalist from South Africa.
- Semenya has an intersex condition called hyperandrogenism, which causes her body to naturally produce testosterone at levels much higher than most women.
- In April of last year, the International Association of Athletics Federations (IAAF) announced new rules that require hyperandrogenous athletes to take medication to lower their testosterone levels in order to compete in female events. Due to the narrow scope of the rule change, many believed it was specifically aimed at Semenya.
- Semenya appealed to the CAS to challenge the rule change. The CAS ruled against Semenya yesterday, siding with the IAAF by a 2-1 margin.
- The decision paves the way for the new rules to go into effect shortly, meaning Semenya will have to continue taking medication to suppress her testosterone output in order to participate in elite track and field events as a female competitor.